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Background: The combination of an inhaled corticosteroid (ICS) and a long-Abstract
acting bronchodilator is recommended in the treatment of patients with chronic
obstructive pulmonary disease (COPD) who have frequent exacerbations.
Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and
tolerability in patients with COPD.
Objective: To evaluate the efficacy and tolerability of budesonide/formoterol
administered via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI)
in patients with COPD.
Methods: This was a 6-month, randomized, double-blind, double-dummy, place-
bo-controlled, parallel-group, multicentre study (NCT00206154) of 1704 patients
aged ≥40 years with moderate to very severe COPD conducted in 194 centres in
the US, Czech Republic, the Netherlands, Poland and South Africa. After 2 weeks
of treatment based on previous therapy (ICSs and short-acting bronchodilators
allowed during the run-in period), patients received one of the following treat-
ments administered twice daily: budesonide/formoterol pMDI 160/4.5 μg × two
inhalations (320/9 μg); budesonide/formoterol pMDI 80/4.5 μg × two inhalations
(160/9 μg); budesonide pMDI 160 μg × two inhalations (320 μg) plus formoterol
DPI 4.5 μg × two inhalations (9 μg); budesonide pMDI 160 μg × two inhalations
(320 μg); formoterol DPI 4.5 μg × two inhalations (9 μg); or placebo.
Main outcome measures: The co-primary efficacy variables were pre-dose
forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.
Results: Budesonide/formoterol 320/9 μg demonstrated significantly greater
improvements in pre-dose FEV1 versus formoterol (p = 0.026; pre-specified
primary comparator) and 1-hour post-dose FEV1 versus budesonide (p < 0.001;
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pre-specified primary comparator); budesonide/formoterol 160/9 μg demonstra-
ted significantly greater improvements versus budesonide (p < 0.001) for 1-hour
post-dose FEV1 but not versus formoterol for pre-dose FEV1. Dyspnoea (mea-
sured using the Breathlessness Diary) and health-related quality-of-life (HR-
QOL) scores (based on the St George’s Respiratory Questionnaire total score)
were significantly improved with both dosage strengths of budesonide/formoterol
compared with budesonide, formoterol and placebo (p ≤ 0.044 for all). Although
not powered a priori for comparisons, the number of exacerbations per patient-
treatment year requiring treatment with oral corticosteroids and/or hospitalization
was numerically (20–25%) lower with the budesonide-containing treatments
(0.710–0.884) versus formoterol (1.098) and placebo (1.110). This result was
driven by the exacerbations requiring treatment with oral corticosteroids (79–120
events). The number of exacerbations resulting in hospitalization was very low
across treatment groups (11–22); the number per patient-treatment year was
significantly different for budesonide/formoterol 320/9 μg (0.158) versus other
treatment groups (0.081–0.108) except budesonide/formoterol 160/9 μg (0.139),
and for budesonide/formoterol 160/9 μg versus formoterol (0.081) [p ≤ 0.05]. All
treatments were generally well tolerated. The incidence of individual non-fatal
serious adverse events was similar across all treatment groups, except COPD,
which was highest in the budesonide/formoterol 320/9 μg group (6.1%) and
lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of
4.3–4.6% in the budesonide/formoterol 160/9 μg, budesonide plus formoterol and
placebo groups. Budesonide/formoterol had a safety profile comparable with that
of the monocomponents and placebo. There was no increase in the incidence of
pneumonia in the active treatment groups relative to placebo.
Conclusions: Budesonide/formoterol pMDI 320/9 μg demonstrated significantly
greater efficacy for pulmonary function on both co-primary endpoints versus the
pre-specified comparators (formoterol DPI 9 μg for pre-dose FEV1 and budeso-
nide pMDI 320 μg for 1-hour post-dose FEV1). Budesonide/formoterol pMDI
160/9 μg demonstrated significantly greater efficacy for 1-hour post-dose FEV1
versus budesonide pMDI 320 μg. Dyspnoea scores and HR-QOL were signifi-
cantly improved with both budesonide/formoterol pMDI dosage strengths versus
both monocomponents and placebo. Both budesonide/formoterol pMDI dosage
strengths were well tolerated relative to the monocomponents and placebo.
Background In patients with COPD, long-acting β2-adre-
noceptor agonists (LABAs) have been shown to
achieve several of these therapeutic goals, includingChronic obstructive pulmonary disease (COPD)
improvement in pulmonary function and COPDis characterized by progressive fixed airflow limita-
symptoms, reduction in rescue medication use andtion and an abnormal inflammatory response to nox- improvement in health-related quality of life (HR-ious stimuli.[1] The goals of COPD therapy include QOL).[2-6] Inhaled corticosteroids (ICSs) reduce the(i) improvements in airflow, exercise tolerance, frequency of exacerbations,[7-9] but have shown in-
health status and COPD symptoms (e.g. dyspnoea); consistent results in terms of reduction in mortality
(ii) prevention of disease progression and exacerba- and modest effects with respect to improvement in
tions; and (iii) a reduction in mortality.[1] pulmonary function.[9-16]
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The combination of the ICS budesonide and the required to have a history of at least one COPD
LABA formoterol administered in a single dry pow- exacerbation treated with a course of oral cortico-
der inhaler (DPI) [Symbicort® Turbuhaler®;1 Astra- steroids and/or antibacterials within 1–12 months
Zeneca, Lund, Sweden] demonstrated significant before screening (visit 1) and documented use of an
improvements in pulmonary function, HR-QOL and inhaled short-acting bronchodilator as rescue med-
symptoms, and a significant reduction in exacerba- ication. At screening, spirometry was performed
tion rate compared with placebo in patients with before and 15–30 minutes after administration of
COPD.[17,18] Moreover, in comparison with the two inhalations of salbutamol (albuterol) pMDI (to-
monocomponents, budesonide/formoterol DPI dem- tal dose 180–200 μg). A prebronchodilator FEV1 of
onstrated significant improvements in forced expir- ≤50% of predicted normal and a prebronchodilator
atory volume in 1 second (FEV1) versus budesonide FEV1/forced vital capacity of <70% were required
alone[17,18] and formoterol alone,[17] and a significant at screening. Additional criteria included a smoking
reduction in the rate of severe and overall COPD history of ≥10 pack-years, a score of ≥2 on the
exacerbations compared with formoterol alone.[17,18] Modified Medical Research Council dyspnoea scale
at the time of screening,[19] and a breathlessness,The present 6-month study evaluated the efficacy
cough and sputum scale (BCSS) score of ≥2 per dayand tolerability of budesonide/formoterol adminis-
for at least half of the 2-week run-in period.tered via a hydrofluoroalkane (HFA) pressurized
metered-dose inhaler (pMDI) [Symbicort® pMDI; Patients were excluded if they had any of the
AstraZeneca, Charnwood, Loughborough, UK] in following conditions: (i) a history of asthma; (ii) a
patients with moderate to very severe COPD. history of allergic rhinitis before 40 years of age;
Budesonide/formoterol pMDI was administered in (iii) significant/unstable cardiovascular disorder;
two dosage strengths (160/4.5 μg × two inhalations (iv) clinically significant respiratory tract disorder
[320/9 μg] and 80/4.5 μg × two inhalations [160/ other than COPD; and (v) homozygous α-1 antitryp-
9 μg]), each administered twice daily, and compared sin deficiency or any other clinically significant co-
with the monocomponents (administered alone or in morbidities that could preclude participation in the
combination via separate inhalers) and placebo. This study or interfere with the study results, as deter-
is the first time that two doses of budesonide in mined by the investigator. Patients were also ex-
combination with a LABA have been evaluated in cluded if they needed additions or alterations to their
the same study in patients with COPD, the results of usual COPD maintenance therapy or an increment
which may provide some insight into the efficacy in rescue therapy due to worsening symptoms within
and safety implications of differing doses of ICS in 30 days before screening or during the run-in
combination with a LABA in clinical practice. period. Oral or ophthalmic non-cardioselective β-
adrenoceptor antagonists, oral corticosteroids, preg-
Patients and Methods nancy and breast-feeding also were exclusionary.
Study Design and TreatmentPatients
The inclusion criteria were designed to enrol This randomized, double-blind, double-dummy,
patients with moderate to very severe COPD who placebo-controlled, parallel-group, 6-month study
had previous exacerbations and were therefore suit- (NCT00206154) was conducted in 194 centres in
able candidates for ICS/LABA combination ther- the US, Czech Republic, the Netherlands, Poland
apy. Current or ex-smokers aged ≥40 years with a and South Africa. The study consisted of a screening
clinical diagnosis of COPD and symptoms for visit (visit 1), a 2-week run-in period, a randomiza-
>2 years were eligible for this study. Patients were tion visit (visit 2), four subsequent visits during the
1 The use of trade names is for product identification purposes only and does not imply endorsement.
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PL bid n = 300
FM DPI 4.5 μg × 2 inhalations (9 μg) bid n = 284
BUD pMDI 160 μg × 2 inhalations (320 μg) bid n = 275
BUD pMDI 160 μg × 2 inhalations (320 μg) bid +
FM DPI 4.5 μg × 2 inhalations (9 μg) bid n = 287
BUD/FM pMDI 80/4.5 μg × 2 inhalations (160/9 μg) bid n = 281
BUD/FM pMDI 160/4.5 μg × 2 inhalations (320/9 μg) bid n = 277










Fig. 1. Study design. To maintain blinding, patients received both a pressurized metered-dose inhaler (pMDI) and a dry powder inhaler
(DPI) containing either active treatment or placebo (PL), or combinations of active treatment and placebo, as appropriate. bid = twice daily;
BUD = budesonide; FM = formoterol; R = randomization.
26-week treatment period and a follow-up telephone Zeneca, Charnwood, Loughborough, UK). Visits
call 30 days after the last study visit. During the 3–6 were scheduled at 1, 2, 4 and 6 months after
2-week run-in period, patients continued ICS mono- randomization. Salbutamol was not to be used with-
therapy if they had previously been receiving ICS in 6 hours before each clinic visit; inhaled ipratropi-
alone or in combination with a LABA, and patients um bromide was not to be used within 8 hours
who had previously been receiving anticholinergic before each clinic visit. Allowed and disallowed
therapies were placed on stable doses of ipratropium concomitant medications are described in table I.
bromide. A short-acting β2-adrenoceptor agonist The study protocol was approved by a review
was allowed for rescue use. At visit 2 (after the run- board and ethics committee at each site, and written
in period), any ICS therapy was discontinued and all informed consent was obtained from patients. The
patients were then given study rescue medication study was performed in accordance with the ethical
(salbutamol pMDI) for as-needed use. principles based on the Declaration of Helsinki and
consistent with the International Conference on Har-At visit 2, eligible patients were randomized in
monization/Good Clinical Practice and applicablebalanced blocks according to a computer-generated
local regulatory requirements.randomization scheme at each site to one of six
treatments administered twice daily (figure 1).
The present study used formoterol DPI (formoterol Efficacy Evaluations
Turbuhaler®; AstraZeneca, So¨derta¨lje, Sweden) as
the formoterol comparator rather than formoterol The co-primary efficacy variables were pre-dose
pMDI. Results from a previous study in patients FEV1 and 1-hour post-dose FEV1, measured at all
with asthma demonstrated equivalent formoterol- clinic visits. Spirometry was performed according to
related bronchodilation when formoterol was ad- American Thoracic Society guidelines.[21] Spirome-
ministered in combination with budesonide via try measurements were performed in the morning at
pMDI or alone via DPI.[20] Budesonide was admin- approximately the same time (±1 hour) at each clinic
istered via an HFA pMDI (budesonide pMDI; Astra- visit, approximately 12 hours after the previous dose
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of study medication. Crapo-predicted normals[22] for pleted the validated Breathlessness Diary, a single-
FEV1 were used. item dyspnoea measure derived from the BCSS,[23]
on a daily basis. The item was scored on a 5-pointSecondary pulmonary function variables includ-
Likert-type scale, ranging from 0 to 4, with highered 12-hour spirometry, pre-dose and 1-hour post-
scores indicating more severe dyspnoea. Based on adose inspiratory capacity (IC), and morning and
previous study,[24] a change of ≥0.2 units in dysp-evening peak expiratory flow (PEF). Twelve-hour
noea score was identified as clinically relevant (i.e.serial FEV1 was performed in a subset of patients
minimal important difference [MID]) and was spec-(n = 618) pre-dose and at 5, 15, 30, 60, 120, 180,
ified a priori. HR-QOL was evaluated at screening,240, 360, 480, 600 and 720 minutes after adminis-
randomization and the end of months 1, 2 and 6tration of study medication at randomization, and
using the St George’s Respiratory Questionnairemonths 2 and 6. Baseline-adjusted average 12-hour
(SGRQ),[25,26] for which a change of 4 units is con-FEV1 (calculated as the area between the 12-hour
sidered clinically meaningful.[27] This threshold forpost-dose FEV1 over time curve and the baseline
a clinically meaningful change was specified a pri-pre-dose FEV1 [defined as the last pre-dose FEV1
ori, and patients were categorized as experiencingbefore the first dose of randomized treatment] divid-
decreases or increases of ≥4 units in the SGRQ totaled by the observation time), FEV1 at 12 hours and
score. COPD exacerbations, defined as worseningmaximum FEV1 were determined. Pre-dose and 1-
of COPD symptoms that required treatment withhour post-dose IC were assessed in this subset of
oral corticosteroids and/or hospitalization, were re-patients. Morning and evening PEF were measured
corded by patients in their diary cards and confirmeddaily before administration of the morning and
by the study coordinators and/or investigators at theevening dose of study medication using a Mini-
clinic visit.Wright® peak flow metre (Clement Clark, Inc.,
Harlow, UK), and the highest of three measurements Secondary symptom variables, including cough
was recorded by patients in their diary cards. and sputum scores, sleep score and rescue med-
Secondary efficacy variables included dyspnoea, ication use, were recorded on a daily basis by pa-
HR-QOL and COPD exacerbations. Patients com- tients. Cough and sputum scores were recorded
Table I. Concomitant medications
Allowed Disallowed
Ephedrine-free (or other bronchodilator-free) antitussives and Long-acting anticholinergics
mucolytics Inhaled LABAs (other than study medication)
Nasal corticosteroids Inhaled SABAs (other than salbutamol [albuterol] for rescue)
Stable-dose non-nebulized ipratropium bromidea Oral β2-adrenoceptor agonists
Oral or ophthalmic cardioselective β-adrenoceptor antagonistsb Ephedrine-containing medication
Study-provided salbutamol (albuterol) as rescue medicationc Leukotriene receptor antagonists and 5-lipoxygenase inhibitors
Medications allowed for exacerbations after randomization: Xanthine-containing derivatives (except in short-term treatment of
oral and parenteral corticosteroids (not depot formulations) exacerbations)
acute use of xanthines Disodium cromoglygates
increased use of inhaled β2-adrenoceptor agonists and Non-cardioselective β-adrenoceptor antagonists
ipratropium bromide ICSs (other than study medication)d
nebulized β2-adrenoceptor agonists and ipratropium bromide
a Allowed if the patient had been receiving anticholinergic treatment before the study (not to be used within 8 hours of each clinic
visit).
b Allowed if the patient had been using β-adrenoceptor antagonists at a constant dose for 6 months before screening (visit 1) without
evidence of bronchospasm.
c Not to be used within 6 hours of each clinic visit.
d Allowed during the run-in period.
ICSs = inhaled corticosteroids; LABA = long-acting β2-adrenoceptor agonist; SABA = short-acting β2-adrenoceptor agonist.
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before the evening dose of study medication, and In all patients, blood and urine samples were
each were assessed on a scale from 0 to 4, with collected, and comprehensive physical examina-
higher scores indicating an increased number of tions were carried out at the time of screening and at
symptoms or more severe symptoms. The BCSS is the end of month 6 or the last visit. Blood samples
the sum total of the individual dyspnoea, cough and were analysed by a central laboratory (Quest Diag-
sputum scores, and the total scores range from 0 to nostics Clinical Laboratories, Van Nuys, CA, USA).
12.[23] Sleep score was recorded before the morning Vital signs, including heart rate and blood pressure,
dose of study medication and assessed on a scale were measured at all clinic visits. 12-Lead ECGs
from 0 to 4, with higher scores indicating more sleep were performed in all patients before and
disturbances (based on the number and/or duration 30–60 minutes after inhalation of study drug at
of night-time awakenings, including early awaken- randomization and at the end of months 2 and 6.
ings, caused by COPD symptoms [e.g. dyspnoea, ECG results were evaluated by a cardiologist in a
cough and chest tightness]). Rescue medication use blinded fashion through an independent ECG ser-
(inhalations/day) was recorded in the morning and vice provider (eResearch Technology, Inc., Phila-
evening before administration of study medication. delphia, PA, USA). Clinically important abnormali-
The percentages of awakening-free nights (defined ties and shifts were identified as follows: heart rate
as nights for which the patient reported a sleep score >100 beats per minute (bpm) or a change of
of 0) and rescue medication-free days (defined as ≥20 bpm from baseline; QT/QTc interval ≥500 msec
days for which the patient reported no daytime or or an increase of >60 msec from baseline. Samples
night-time rescue medication use) were calculated. to assess 24-hour urinary cortisol levels were col-
lected in a subset of patients (n = 437) at or before
randomization and within 1 week before the 6-Safety Evaluations
month visit.
The incidence of adverse events (AEs), serious
AEs (SAEs) and discontinuations due to AEs Statistical Analyses
(DAEs) was assessed. AEs were recorded by the
patient on a diary card throughout the study. AEs The efficacy analysis set (i.e. intention-to-treat
also were collected at the beginning of each clinic population) included all randomized patients who
visit and during the final follow-up telephone call. received at least one dose of study medication and
Symptoms or signs consistent with COPD (e.g. contributed sufficient data for at least one co-prima-
bronchitis, cough, phlegm, increased sputum, dysp- ry or secondary efficacy endpoint during the ran-
noea, wheeze) were to be reported as AEs only if domized treatment period. The safety analysis popu-
they were serious, new to the patient, inconsistent lation included randomized patients who had re-
with the patient’s pre-existing COPD history within ceived at least one dose of study medication and
1 year of the screening visit or when they resulted in from whom any post-randomization data were avail-
discontinuation from the study. Investigators as- able. For the subsets of patients who underwent
sessed the causal relationship of AEs to study med- serial spirometry and 24-hour urinary cortisol mea-
ication. surement, analysis sets were defined as randomized,
treated patients who had baseline and on-treatmentAEs representing typical class effects associated
values for the variable being assessed.with exposure to corticosteroids (e.g. local, sys-
temic) or β2-adrenoceptor agonists (e.g. cardiac ef- A sample size of 190 evaluable patients per treat-
fects, tremor, anxiety) were described. AEs of oral ment group was estimated to provide ≥90% power
candidiasis were based on history/physical examina- to detect a difference of 0.1 L (assuming a standard
tion and did not require confirmatory culture. Other deviation of 0.3 L) in the change from baseline in
AEs of interest included those related to pneumonia pre-dose FEV1 between treatment groups. The sam-
and other respiratory tract infections. ple size also provided 80–90% power to detect dif-
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ferences in dyspnoea scores and SGRQ total score. primary efficacy variables. AE variables were sum-
marized descriptively.All hypothesis testing was conducted using 2-sided
tests; p ≤ 0.05 was considered statistically signif-
Resultsicant.
The prespecified primary comparators for the co-
primary efficacy variables were (i) formoterol DPI Patients
for pre-dose FEV1 to demonstrate the contribution
Patient disposition is shown in figure 2. Discon-of budesonide to the anti-inflammatory action of
tinuation rates were significantly lower in thebudesonide/formoterol pMDI; and (ii) budesonide
budesonide/formoterol 160/9 μg and 320/9 μgpMDI for 1-hour post-dose FEV1 to demonstrate the groups compared with the placebo, budesonide andcontribution of formoterol to the bronchodilator ac-
formoterol groups (p ≤ 0.018). Discontinuation ratestion of budesonide/formoterol pMDI. Analyses of
were not significantly different for either of thethe primary and key secondary efficacy endpoints
monocomponents compared with placebo. The
were adjusted for multiplicity using a sequential
overall discontinuation rate was higher in the USapproach to hypothesis testing at the 5% signifi- (28.6%) than in non-US countries (12.2%).cance level. No formal hypothesis testing of the
Demographic and baseline disease characteristicssafety data was performed, although treatment dif-
were generally similar across treatment groupsferences for certain variables are described with (table II). Approximately half of the patients wereconfidence intervals and p-values (used as flagging
≥65 years of age and approximately 12% weredevices).
≥75 years of age. Most patients had severe (58.2%)
Changes from baseline in the co-primary efficacy or very severe (22%) COPD, while 19.3% had mod-
variables were analysed using an analysis of co- erate and 0.3% had mild COPD, based on post-
variance (ANCOVA) model, adjusting for treat- bronchodilator FEV1 at screening and 2007 Global
ment, country and baseline. Changes from baseline Initiative for Chronic Obstructive Lung Disease cri-
in other secondary efficacy variables were analysed teria (0.2% had missing data).[1] The mean pre-
using methodology similar to that described for the bronchodilator FEV1 at screening was approximate-
co-primary efficacy variables. A Cochrane-Mantel- ly 34% of predicted normal. Approximately
Haenszel test, adjusted for country and prespecified 40–45% of participants were current smokers with a
in the statistical analysis plan, was used to separately median smoking history of 40 pack-years. Co-mor-
evaluate the percentages of patients with increases bid conditions affecting the overall population in-
and decreases that met the MID for SGRQ total cluded hypertension (42%), lipid profile abnormali-
score. The number of exacerbations per patient- ties (24%), cardiac disease (18%), diabetes mellitus
treatment year was compared between treatment (10%), osteoporosis (8%) and cataracts (5%). Dem-
groups using a Poisson regression model, adjusting ographic and baseline disease characteristics were
for country, differential time from randomization generally similar across regions, with the exception
and over dispersion. In addition, a sensitivity ana- that higher percentages of females and Black pa-
lysis, including a region-by-treatment interaction tients were reported in US (41.5% and 8.2%, respec-
term, was added to the model for the co-primary tively) versus non-US regions (24.8% and 0.5%,
variables to test for treatment differences by region. respectively).
Geometric mean 24-hour urinary cortisol levels
Efficacy Evaluationsat the end of treatment were compared between
treatment groups using a multiplicative ANCOVA
Co-Primary Efficacy Variablesmodel. Mean changes from baseline in ECG vari-
ables were compared between treatment groups us- Improvements in pre-dose FEV1 were signifi-
ing methodology similar to that described for the co- cantly greater in patients who were treated with
© 2008 Adis Data Information BV. All rights reserved. Drugs 2008; 68 (14)






































Not randomized (n = 677)
• Eligibility criteria not fulfilled (n = 439)
• Withdrew consent (n = 129)
• AE (n = 46)
• Other (n = 42)
• Lost to follow-up (n = 20)
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(n = 3) 
• AE (n = 28) 
• Withdrew 
consent 
(n = 27) 
• Lost to 
follow-up 
(n = 7) 
• Other (n = 12)   
Discontinued 




(n = 4) 
• AE (n = 34) 
• Withdrew 
consent 
(n = 12) 
• Lost to 
follow-up 
(n = 1) 
• Other (n = 10)   
Discontinued 




(n = 2) 
• AE (n = 26) 
• Withdrew 
consent 
(n = 20) 
• Lost to 
follow-up 
(n = 4) 
• Other (n = 10)  
• Missing (n = 1) 
Discontinued 




(n = 4) 
• AE (n = 14) 
• Withdrew 
consent 
(n = 14) 
• Lost to 
follow-up 
(n = 6) 
• Other (n = 10)   
Discontinued 




(n = 1) 
• AE (n = 20) 
• Withdrew 
consent 
(n = 8) 
• Lost to 
follow-up 
(n = 3) 
• Other (n = 6)   
Discontinued 




(n = 3) 
• AE (n = 21) 
• Withdrew 
consent 
(n = 6) 
• Lost to 
follow-up
(n = 4) 
• Other (n = 5)   
Discontinued 
(n = 326; 19.1%) 
• Eligibility 
criteria not 
fulfilled           
(n = 17) 
• AE (n = 143) 
• Withdrew 
consent 
(n = 87) 
• Lost to 
follow-up 
(n = 25) 
• Other (n = 53)  
• Missing (n = 1)  
Fig. 2. Patient disposition. 1 The efficacy analysis set included 1697 patients. Seven patients were excluded because of an early study site
closure; data from these patients were included in the safety analysis set. AE = adverse event; BUD = budesonide; DPI = dry powder
inhaler; FM = formoterol; med = medication; PL = placebo; pMDI = pressurized metered-dose inhaler.
budesonide/formoterol 320/9 μg compared with for- apparent at the first assessment after randomization
(month 1) following treatment with both budeso-moterol (primary comparison), budesonide and pla-
nide/formoterol dosage strengths and were generallycebo (p ≤ 0.026; table III). Budesonide/formoterol
maintained over the 6-month treatment period with160/9 μg demonstrated significantly greater im-
budesonide/formoterol 320/9 μg (figure 3a).provements in pre-dose FEV1 compared with
budesonide and placebo (p ≤ 0.002), but not com- Improvements in 1-hour post-dose FEV1 were
pared with formoterol (the pre-specified primary significantly greater in the budesonide/formoter-
comparator). Treatment with formoterol also result- ol 320/9 μg group compared with the budesonide
ed in significantly greater improvements in pre-dose (p < 0.001; primary comparison), formoterol
FEV1 compared with placebo (p = 0.037). Patients (p = 0.039) and placebo (p < 0.001) groups (table
treated with budesonide did not experience signif- III). Treatment with budesonide/formoterol 160/
icant improvements in pre-dose FEV1 compared 9 μg resulted in significantly greater improvements
in 1-hour post-dose FEV1 compared with budeso-with placebo. Improvements in pre-dose FEV1 were
© 2008 Adis Data Information BV. All rights reserved. Drugs 2008; 68 (14)
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nide and placebo (p < 0.001). Formoterol also result-
ed in significantly greater improvements in 1-hour
post-dose FEV1 compared with placebo (p < 0.001;
table III). Improvements were apparent on the
day of randomization and were maintained over the
6-month treatment period after treatment with both
budesonide/formoterol dosage strengths and formo-
terol (figure 3b).
The results of the region-by-treatment inter-
action sensitivity analyses for the co-primary effi-
cacy variables were not significant for either vari-
able (p ≥ 0.148).
Secondary Pulmonary Function Variables
Both budesonide/formoterol dosage strengths re-
sulted in significantly greater mean improvements
in baseline-adjusted average 12-hour FEV1 com-
pared with budesonide and placebo at randomiza-
tion and end of treatment (p ≤ 0.012, all compari-
sons); budesonide/formoterol 320/9 μg demonstra-
ted significantly greater improvements compared
with formoterol at end of treatment (p = 0.030).
Patients receiving budesonide/formoterol combina-
tion therapy or formoterol alone experienced a mean
improvement in FEV1 of approximately 15–18%
at 5 minutes after dose administration at the random-
ization visit (figure 4a) and end of treatment (figure
4b); an improvement in FEV1 of ≥15% is generally
considered clinically significant. At the 12-hour
timepoint, significant improvements in FEV1 were
observed at randomization for both budesonide/for-
moterol dosage strengths compared with budesonide
and placebo (p ≤ 0.006) and for formoterol com-
pared with placebo (p < 0.001); this effect was
maintained at end of treatment for budesonide/for-
moterol 320/9 μg (p ≤ 0.019 vs budesonide, formo-
terol and placebo). Significantly greater adjusted
mean improvements from baseline in maximum
FEV1 during 12-hour serial spirometry were observ-
ed on the day of randomization for budesonide/
formoterol 320/9 μg (0.32 L) and 160/9 μg (0.30 L)
compared with budesonide (0.15 L) and placebo
(0.16 L), and for formoterol (0.28 L) compared with
placebo (0.16 L) [p < 0.001 for all comparisons]. At
the end of treatment, adjusted mean improvements
in maximum FEV1 were significantly greater with
































































































































































































































































































































































































































































1986 Tashkin et al.
ferent between the treatment groups. Improvements
in morning and evening PEF were significantly
greater for both budesonide/formoterol dosage
strengths compared with budesonide, formoterol
and placebo (p ≤ 0.016) and for formoterol com-
pared with placebo (p ≤ 0.004; table III).
Secondary Efficacy Variables
Patients treated with both budesonide/formoterol
dosage strengths experienced significantly greater
improvements in dyspnoea scores compared with
budesonide, formoterol and placebo (p ≤ 0.044;
table IV). Improvements in dyspnoea were clinically
meaningful (i.e. reduction of ≥0.2 units [MID]) for
all active treatment groups compared with their





































































BUD/FM pMDI 320/9 μg
BUD/FM pMDI 160/9 μg
BUD pMDI 320 μg + FM DPI 9 μg
BUD pMDI 320 μg









Fig. 3. Adjusted mean change from baseline in (a) pre-dose forced
expiratory volume in 1 second (FEV1) and (b) 1-hour post-dose
FEV1 by study visit over the randomized treatment period and end
of treatment (EOT). BUD = budesonide; DPI = dry powder inhaler;
FM = formoterol; PL = placebo; pMDI = pressurized metered-dose
inhaler. * p < 0.01 vs PL; † p < 0.05 vs BUD pMDI; ‡ p < 0.05 vs FM
DPI.
budesonide/formoterol 320/9 μg (0.27 L) compared
with placebo (0.14 L) [p = 0.003] and for budeso-
nide/formoterol 320/9 μg (0.27 L) and 160/9 μg
(0.21 L) compared with budesonide (0.11 L)
[p ≤ 0.014]. In patients undergoing serial spirome-
try, adjusted mean improvements in 1-hour post-
dose IC values over the treatment period were sig-
nificantly greater after treatment with budesonide/
formoterol 320/9 μg (0.29 L) and 160/9 μg (0.29 L)
compared with budesonide (0.08 L) and placebo
(0.10 L; all comparisons p < 0.001), and with formo-
terol (0.34 L) compared with placebo (p < 0.001).








































BUD/FM pMDI 320/9 μg
BUD/FM pMDI 160/9 μg
BUD pMDI 320 μg + FM DPI 9 μg
BUD pMDI 320 μg
FM DPI 9 μg
PL
Fig. 4. Mean percentage change from baseline (defined as the pre-
dose FEV1 value before the first dose of randomized treatment) in
forced expiratory volume in 1 second (FEV1) over 12 hours at
(a) randomization and (b) end of treatment (EOT). The first time
point for assessment occurred 5 minutes after administration of
study medication on the day of randomization and EOT.
BUD = budesonide; DPI = dry powder inhaler; FM = formoterol;
PL = placebo; pMDI = pressurized metered-dose inhaler.
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terol dosage strength reached the prespecified MID merically lower (approximately 20–25%), although
not significantly different (p ≥ 0.060), in the budes-compared with placebo (based on comparison of
onide-containing groups (budesonide/formoterolleast squares mean changes from baseline).
320/9 μg [0.884], budesonide/formoterol 160/9 μgBoth budesonide/formoterol dosage strengths re-
[0.851], budesonide plus formoterol [0.710] andsulted in significant improvements in the COPD-
budesonide [0.882]) compared with the formoterolrelated symptoms of breathlessness, cough and spu- (1.098) and placebo (1.110) groups. This resulttum (summed as the BCSS), and in sleep score and
was driven by the category of COPD exacerbationspercentage of awakening-free nights compared with
requiring treatment with oral corticosteroids:placebo (p ≤ 0.029; table IV). Daily rescue med-
budesonide/formoterol 320/9 μg (0.824), budeso-ication use was significantly decreased and rescue
nide/formoterol 160/9 μg (0.826), budesonide plusmedication-free days were significantly increased
formoterol (0.684), budesonide (0.828), formoterolwith both budesonide/formoterol dosage strengths (1.104) and placebo (1.068); differences were sig-compared with budesonide and placebo (p < 0.001),
nificant for budesonide/formoterol (both dosageand with formoterol compared with placebo
strengths) compared with formoterol (p ≤ 0.043).(p ≤ 0.002).
The total number of COPD exacerbations requiring
Improvements in the SGRQ total scores were hospitalization was very low in all treatment groups
significantly greater (p ≤ 0.035) in both budesonide/ (range 11–22); the number of events per patient-
formoterol groups compared with the budesonide, treatment year was significantly different for
formoterol and placebo groups (table V). These budesonide/formoterol 320/9 μg (0.158) compared
improvements were clinically meaningful (i.e. re- with other treatment groups (0.081–0.108) except
duction from baseline of ≥4 points) for both budeso- budesonide/formoterol 160/9 μg (0.139), and for
nide/formoterol dosage strengths compared with budesonide/formoterol 160/9 μg compared with for-
their baseline values at all timepoints assessed (fig- moterol (0.081) (p ≤ 0.05).
ure 5). However, differences between the active
treatment and placebo groups in SGRQ total score Safety Evaluations
did not reach the MID at the end of the treatment
period (based on comparison of least squares mean The mean duration of exposure to randomized
changes from baseline). A significantly (p ≤ 0.018) treatment was lowest in the placebo group (150.0
greater percentage of patients in the budesonide/ days) compared with the budesonide/formoterol
formoterol 320/9 μg (45.5%) and budesonide/for- 320/9 μg (166.5 days), budesonide/formoterol 160/
moterol 160/9 μg (45.4%) groups demonstrated a 9 μg (168.3 days) and budesonide plus formoterol
clinically meaningful decrease (i.e. improvement) (164.6 days) groups. Both budesonide/formoterol
from baseline to end of treatment in SGRQ total dosage strengths were well tolerated relative to
score compared with patients in the placebo group budesonide, formoterol and placebo. The percentage
(35.0%). Conversely, the percentage of patients with of patients with at least one AE was generally simi-
increases (i.e. worsening) in SGRQ total score from lar across treatment groups: budesonide/formoterol
baseline to end of treatment was significantly 320/9 μg (57.4%), budesonide/formoterol 160/9 μg
(p ≤ 0.047) lower in the budesonide/formoterol 320/ (52.3%), budesonide plus formoterol (49.5%),
9 μg (22.5%) and budesonide/formoterol 160/9 μg budesonide (57.5%), formoterol (56.7%) and place-
(23.3%) groups compared with the placebo (31.1%) bo (50.7%). Overall, the majority of AEs were of
group. mild (51.4%) or moderate (36.1%) intensity, with a
similar distribution of intensities observed acrossWhile this study was not powered to show a
treatment groups.difference in exacerbations, the number of COPD
exacerbations (requiring oral corticosteroids and/or The most commonly reported AEs (by ≥3% of
hospitalization) per patient-treatment year was nu- randomized patients) were COPD, nasopharyngitis,
© 2008 Adis Data Information BV. All rights reserved. Drugs 2008; 68 (14)
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1992 Tashkin et al.
oral candidiasis, bronchitis, sinusitis and diarrhoea.
COPD was the most commonly reported AE and
occurred at a higher incidence in the formoterol
group (17.6%) compared with all other treatment
groups (10.5% [budesonide plus formoterol] to
13.4% [budesonide/formoterol 320/9 μg]). The per-
centage of patients with drug-related AEs was low
and similar across treatment groups (table VI).
DAEs occurred in 133 patients: 19 (6.9%) in the
budesonide/formoterol 320/9 μg group, 19 (6.8%) in
the budesonide/formoterol 160/9 μg group, 13
(4.5%) in the budesonide plus formoterol group, 25
(9.1%) in the budesonide group, 32 (11.3%) in the
formoterol group and 25 (8.3%) in the placebo
group. The most common DAE was COPD, which
occurred at a higher incidence in the budesonide
(5.8%), formoterol (7.4%) and placebo (5%) groups
compared with the budesonide and formoterol com-
bination therapy groups (2.9–3.8%).
Considering the severity of the COPD population
in this study, there were only 11 deaths reported
during randomized treatment, all of which were
classified as SAEs that were not considered to be
related to the study medication. Three deaths oc-
curred in the budesonide/formoterol 320/9 μg group
(nerve root lesion and metastatic lung cancer; car-
diac failure; hip fracture and subsequent cardiopul-
monary failure), four in the budesonide/formoterol
160/9 μg group (COPD; cardiac arrest; congestive
heart failure and COPD; COPD), two in the budeso-
nide group (COPD; cerebrovascular accident), one
in the formoterol group (myocardial infarction) and
one in the placebo group (subarachnoid haemor-
rhage).
The incidence of individual non-fatal SAEs was
similar across treatment groups, except for COPD,
which was highest in the budesonide/formoterol
320/9 μg group, lowest in the budesonide and for-
moterol groups and similar in the budesonide/for-
moterol 160/9 μg, budesonide plus formoterol and
placebo groups (table VII). Overall, the most com-
mon individual non-fatal SAEs (occurring in at least
three randomized patients) were COPD (4.5%),
pneumonia (0.6%), atrial fibrillation (0.5%), pros-
tate cancer (0.2%), congestive heart failure (0.2%),
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Fig. 5. Adjusted mean changes in the St George’s Respiratory Questionnaire (SGRQ) total scores from baseline to the end of months 1, 2
and 6, and to the last assessment during randomized treatment (end of treatment [EOT]). Baseline was defined as the last assessment
before the first dose of randomized treatment. BUD = budesonide; DPI = dry powder inhaler; FM = formoterol; MID = minimal important
difference; PL = placebo; pMDI = pressurized metered-dose inhaler; * p < 0.05 vs BUD pMDI + FM DPI; † p < 0.05 vs BUD pMDI; ‡ p < 0.05
vs FM DPI; § p < 0.05 vs PL.
respiratory failure (0.2%) and acute bronchitis was low, with a similar incidence observed across
(0.2%). The overall incidence of non-fatal SAEs, all treatment groups (2.8–3.5%).
unadjusted for treatment exposure time, was 11.2% Despite the known association of ICSs with
in the budesonide/formoterol 320/9 μg group, pneumonia,[13] there was no difference between
10.7% in the budesonide/formoterol 160/9 μg treatment groups in the incidence of pneumonia-
group, 9.1% in the budesonide plus formoterol
related AEs (table VIII). For lung infections other
group, 9.5% in the budesonide group, 8.1% in the than pneumonia, the incidence was higher in all
formoterol group and 8.3% in the placebo group.
active treatment groups, except budesonide/formo-
terol 160/9 μg, compared with the placebo group;The incidence of AEs typically associated with
these differences were driven largely by bronchitislocal effects of corticosteroids (e.g. candidiasis,
(table VIII). Two patients had DAEs of pneumoniavoice effects) was highest in the budesonide/formo-
(one in the budesonide group and one in the placeboterol 320/9 μg (6.9%) and budesonide (5.5%)
group) and 13 patients had pneumonia-related SAEsgroups, and lowest in the budesonide/formoterol
that occurred during or after the randomized treat-160/9 μg (3.2%), budesonide plus formoterol
ment period with no preponderance for any specific(3.1%), formoterol (3.2%) and placebo (2.3%)
treatment group noted (budesonide/formoterol 320/groups. The incidence of AEs potentially associated
9 μg [n = 1]; budesonide/formoterol 160/9 μgwith systemic effects of corticosteroids (e.g. bone
[n = 3]; budesonide plus formoterol [n = 2]; budeso-effects, diabetes control, skin effects, weight gain,
nide [n = 3]; formoterol [n = 3]; placebo [n = 1]).ocular effects, taste effects, adrenal suppression)
© 2008 Adis Data Information BV. All rights reserved. Drugs 2008; 68 (14)
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Table VI. Commonly reported adverse events (AEs) that were considered to be related to study medication by the investigator and reported
by at least three patients
Variable BUD/FM pMDI BUD pMDI BUD pMDI FM DPI PL
320/9 μg 160/9 μg 320 μg + 320 μg 9 μg (n = 300)
(n = 277) (n = 281) FM DPI 9 μg (n = 275) (n = 284)
(n = 287)
Mean exposure [days] (SD) 166.5 (41.3) 168.3 (37.7) 164.6 (40.3) 157.1 (51.3) 156.3 (53.2) 150.0 (60.2)
Patients with ≥1 drug-related 24 (8.7) 24 (8.5) 17 (5.9) 22 (8.0) 22 (7.7) 18 (6.0)
AE [n] (%)
Oral candidiasis 7 (2.5) 5 (1.8) 4 (1.4) 8 (2.9) 5 (1.8) 4 (1.3)
COPD 2 (0.7) 4 (1.4) 1 (0.3) 0 8 (2.8) 3 (1.0)
Dysphonia 4 (1.4) 0 1 (0.3) 2 (0.7) 2 (0.7) 1 (0.3)
Headache 1 (0.4) 2 (0.7) 1 (0.3) 1 (0.4) 3 (1.1) 2 (0.7)
Pharyngolaryngeal pain 2 (0.7) 1 (0.4) 0 4 (1.5) 2 (0.7) 0
Acute bronchitis 1 (0.4) 0 1 (0.3) 0 2 (0.7) 1 (0.3)
Dyspnoea 1 (0.4) 1 (0.4) 0 1 (0.4) 0 2 (0.7)
Dizziness 1 (0.4) 2 (0.7) 0 0 1 (0.4) 0
Muscle spasm 1 (0.4) 0 1 (0.3) 1 (0.4) 1 (0.4) 0
Weight increased 0 1 (0.4) 1 (0.3) 1 (0.4) 0 1 (0.3)
Cough 0 0 1 (0.3) 0 1 (0.4) 1 (0.3)
Diarrhoea 0 0 1 (0.3) 1 (0.4) 1 (0.4) 0
Dry mouth 1 (0.4) 0 1 (0.3) 1 (0.4) 0 0
Insomnia 0 1 (0.4) 0 1 (0.4) 0 1 (0.3)
Palpitation 1 (0.4) 0 0 1 (0.4) 1 (0.4) 0
Tremor 0 3 (1.1) 0 0 0 0
BUD = budesonide; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FM = formoterol; PL = placebo;
pMDI = pressurized metered-dose inhaler.
The overall incidence of AEs potentially or typi- Compared with patients in non-US regions, pa-
tients enrolled in centres in the US had a highercally associated with β2-adrenoceptor agonists ef-
overall incidence of AEs (63.6% vs 46.8%), a higherfects (i.e. headache, sleep effects, muscle cramps,
overall incidence of AEs per patient-treatment yearanxiety, serum potassium decrease, serum glucose (3.9 vs 2.0) and a higher incidence of drug-relatedincrease, palpitation, tremor, tachycardia, agitation)
AEs (13.2% vs 3.3%). The incidence of individual
was low (5.9%), ranging from 4.9% (budesonide AEs generally was similar across the regions.
plus formoterol) to 7.5% (budesonide/formoterol
Clinically significant changes in vital signs,160/9 μg) across treatment groups. The incidence of
physical examinations or ECG measures were rare,
cardiac-related AEs was slightly higher in the
with no clinically important differences observedbudesonide plus formoterol (6.6%) and budesonide between the budesonide/formoterol groups and the(6.5%) groups compared with the budesonide/for- budesonide, formoterol and placebo groups. There
moterol 320/9 μg (5.1%), budesonide/formoterol were no clinically important differences between the
160/9 μg (5.3%), formoterol (4.6%) and placebo treatment groups in mean changes from baseline,
(4%) groups. The most common cardiovascular- shifts from baseline or the incidence of clinically
important abnormalities for ECG variables.related AEs were hypertension (1.4%), atrial fibril-
lation (0.6%), angina pectoris (0.4%), congestive The observed changes from baseline and differ-
heart failure (0.4%), coronary artery disease (0.4%), ences between the treatment groups in geometric
blood pressure increase (0.4%) and myocardial is- mean 24-hour urinary cortisol (nmol/24 hours) were
chaemia (0.3%). not considered clinically important. Geometric
© 2008 Adis Data Information BV. All rights reserved. Drugs 2008; 68 (14)
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mean 24-hour urinary cortisol values in the formo- the budesonide/formoterol 320/9 μg group, three in
terol group increased by 30.6% from baseline at the budesonide plus formoterol group, two in the
month 6 and by 29.2% from baseline at end of budesonide group and one in the placebo group.
treatment, while values in the budesonide-contain-
ing treatment groups decreased by 23.6–35.8% Discussion
from baseline to month 6 and by 24.2–35.8% from
baseline at end of treatment. Treatment with placebo The results of the present study demonstrated the
resulted in slight decreases in geometric mean 24- efficacy of budesonide/formoterol 320/9 μg for both
hour urinary cortisol at month 6 (6.1%) and end of co-primary endpoints (pre-dose FEV1 and 1-hour
treatment (7.1%). Adjusted geometric mean 24-hour post-dose FEV1) compared with formoterol 9 μg,
urinary cortisol values at months 6 and end of treat- budesonide 320 μg and placebo in patients with
ment were significantly lower for both budesonide/ moderate to very severe COPD, indicating the indi-
formoterol dosage strengths compared with formo- vidual contributions of budesonide and formoterol.
terol (p ≤ 0.001) and for budesonide/formoterol 320/ Budesonide/formoterol 160/9 μg also demonstrated
9 μg and budesonide compared with placebo significantly better results on both co-primary end-
(p ≤ 0.023), and significantly higher for formoterol points compared with budesonide and placebo, but
compared with placebo (p ≤ 0.038). Ten patients had not compared with formoterol; the latter finding
a shift in 24-hour urinary cortisol from normal at may be related to the substantial efficacy observed
baseline to low at end of treatment: four patients in with formoterol.
Table VII. Incidence of non-fatal serious adverse events (SAEs) occurring during the randomized treatment period and reported by at least
two patients [n (%)]
Adverse event BUD/FM pMDI BUD pMDI BUD pMDI FM DPI PL
320/9 μg 160/9 μg 320 μg + 320 μg 9 μg (n = 300)
(n = 277) (n = 281) FM DPI 9 μg (n = 275) (n = 284)
(n = 287)
Patients with ≥1 SAE 31 (11.2) 30 (10.7) 26 (9.1) 26 (9.5) 23 (8.1) 25 (8.3)
COPD 17 (6.1) 13 (4.6) 13 (4.5) 10 (3.6) 11 (3.9) 13 (4.3)
Pneumonia 1 (0.4) 2 (0.7) 2 (0.7) 3 (1.1) 1 (0.4) 1 (0.3)
Atrial fibrillation 1 (0.4) 2 (0.7) 0 2 (0.7) 1 (0.4) 2 (0.7)
Prostate cancer 1 (0.4) 2 (0.7) 0 0 0 1 (0.3)
Acute bronchitis 1 (0.4) 2 (0.7) 0 0 0 0
Congestive heart failure 1 (0.4) 0 0 2 (0.7) 0 0
Respiratory failure 0 1 (0.4) 1 (0.3) 0 1 (0.4) 0
Abdominal pain 0 0 0 1 (0.4) 0 1 (0.3)
Acute myocardial infarction 0 1 (0.4) 0 1 (0.4) 0 0
Angina pectoris 0 0 1 (0.3) 0 1 (0.4) 0
Aortic aneurysm 0 1 (0.4) 0 1 (0.4) 0 0
Bronchopneumonia 0 1 (0.4) 0 0 1 (0.4) 0
Acute cholecystitis 0 0 1 (0.3) 0 0 1 (0.3)
Coronary artery disease 1 (0.4) 0 0 0 1 (0.4) 0
Lower limb fracture 0 0 0 1 (0.4) 1 (0.4) 0
Lung squamous cell carcinoma 0 1 (0.4) 1 (0.3) 0 0 0
(stage unspecified)
Myocardial ischaemia 0 0 1 (0.3) 0 0 1 (0.3)
Non-cardiac chest pain 1 (0.4) 0 0 0 1 (0.4) 0
Pneumothorax 0 0 0 2 (0.7) 0 0
BUD = budesonide; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FM = formoterol; PL = placebo;
pMDI = pressurized metered-dose inhaler.
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Table VIII. Adverse events that are potentially related to lung infections [n (%)]
Adverse event BUD/FM pMDI BUD pMDI BUD pMDI FM DPI PL
320/9 μg 160/9 μg 320 μg + 320 μg 9 μg (n = 300)
(n = 277) (n = 281) FM DPI 9 μg (n = 275) (n = 284)
(n = 287)
Pneumonia-related (total) 3 (1.1) 7 (2.5) 3 (1.0) 5 (1.8) 5 (1.8) 4 (1.3)
pneumonia 3 (1.1) 6 (2.1) 3 (1.0) 5 (1.8) 3 (1.1) 3 (1.0)
bronchopneumonia 0 1 (0.4) 0 0 1 (0.4) 1 (0.3)
pneumococcal pneumonia 0 0 0 0 1 (0.4) 0
Potential lung infections other than pneumonia (total) 21 (7.6) 9 (3.2) 18 (6.3) 17 (6.2) 13 (4.6) 10 (3.3)
bronchitisa 18 (6.5) 8 (2.8) 15 (5.2) 13 (4.7) 11 (3.9) 9 (3.0)
lower respiratory tract infection (bacterial) 2 (0.7) 1 (0.4) 2 (0.7) 1 (0.4) 2 (0.7) 0
lower respiratory tract infection 1 (0.4) 0 1 (0.3) 0 0 1 (0.3)
lower respiratory tract infection (viral) 0 0 0 2 (0.7) 0 0
lung infection 0 0 0 1 (0.4) 0 0
a The aetiology of ‘bronchitis’ could be infectious or non-infectious.
BUD = budesonide; DPI = dry powder inhaler; FM = formoterol; PL = placebo; pMDI = pressurized metered-dose inhaler.
The population of the present study was selected observed differences may be related to the differing
to include patients with moderate to very severe methodologies used during the run-in periods of
COPD who had experienced exacerbations and were these studies. Previous studies that demonstrated
therefore likely to be treated with ICS/LABA com- significant improvements from baseline with ICS
bination therapy. Consequently, all patients were compared with placebo evaluated pulmonary func-
current (40–45% of patients) or previous smokers tion using baseline values after a run-in period
with a median smoking history of 40 pack-years. during which patients received rescue medication
This study allowed enrolment of patients with sig- alone.[18,28,29] Treatment with rescue medication
nificant co-morbidities, such as hypertension, lipid alone during the run-in period may have affected
profile abnormalities, cardiac disease, diabetes, os- baseline values and margins for improvement
teoporosis and cataracts, therefore resembling real during the randomized treatment period in those
clinical practice conditions. By allowing patients to studies. In contrast, patients in the present study
receive therapy based on previous treatment during were generally maintained on their previous ther-
the run-in period, the study was designed to avoid apy, including ICS, because of the widespread avail-
substantial deterioration in COPD symptoms during ability of long-term maintenance therapies at the
the run-in period before patients began randomized time the present study was conducted. Therefore, in
treatment. the present study, patients received therapy during
the run-in period based on their previous treatmentIn the present study, treatment with budesonide
to avoid substantial deterioration in COPD symp-
alone did not improve pre-dose FEV1 or 1-hour
toms, which may have accounted for the lack ofpost-dose FEV1 compared with placebo. These re- demonstrable effect of budesonide alone on FEV1.sults are similar to those reported by Calverley et
However, the significantly greater improvements in
al.,[17] who demonstrated no significant improve-
pre-dose FEV1 and 1-hour post-dose FEV1 observedment in post-dose FEV1 following treatment with
with budesonide/formoterol 320/9 μg comparedbudesonide compared with placebo in patients with
with formoterol in the present study suggest that
severe COPD. In contrast, other studies have dem- budesonide in combination with formoterol contrib-
onstrated significant improvements in pre- and post-
utes to improvement in pulmonary function.dose FEV1 in patients with moderate to very severe
COPD receiving budesonide [18] or fluticasone pro- The present study is the first to evaluate two
pionate[28,29] alone compared with placebo. These dosage strengths of ICS/LABA combination therapy
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in the same study in patients with COPD. The results with budesonide[18] or placebo.[17,18] Significantly
greater improvements in HR-QOL (based on theof direct comparisons demonstrated no significant
SGRQ total score) also were experienced by patientsdifferences between the two budesonide/formoterol
in both budesonide/formoterol pMDI treatmentpMDI dosage strengths for any variable. However,
groups compared with patients in the budesonide,some differences were noted between the two
formoterol and placebo groups in the present study.budesonide/formoterol dosage strengths with regard
Similarly, significant improvements in the SGRQto changes from baseline in pulmonary function. In
total score have been reported in patients withparticular, budesonide/formoterol 320/9 μg, but not
COPD treated with budesonide/formoterol DPI 320/budesonide/formoterol 160/9 μg, resulted in signifi-
9 μg administered twice daily compared withcantly greater improvements from baseline in both
those treated with the monocomponents[17] or place-pre-dose FEV1 and 1-hour post-dose FEV1 (co-
bo.[17,18] These results indicate that both budesonideprimary efficacy variables) compared with formo-
and formoterol contribute to the efficacy of the com-terol. Both budesonide/formoterol dosage strengths
bination product by improving COPD symptoms.demonstrated significantly greater improvements
from baseline in measures of pulmonary function Reductions in exacerbations of 20–25% were
compared with placebo, and both dosage strengths observed for budesonide-containing treatments
demonstrated a rapid onset of bronchodilation compared with formoterol and placebo. The magni-
(within 5 minutes post-dose). However, better main- tude of these reductions in exacerbation rates is
tenance of pulmonary function was observed similar to that observed in previous studies evaluat-
throughout the study period with budesonide/formo- ing the effects of budesonide/formoterol[17,18] or
terol 320/9 μg compared with budesonide/formoter- fluticasone propionate/salmeterol.[13,30] Although
ol 160/9 μg, as suggested by the changes from these previous studies demonstrated statistical sig-
baseline in the co-primary efficacy variables and in nificance for this outcome, the present study was not
FEV1 over 12 hours at the end of treatment com- powered to demonstrate differences between treat-
pared with the day of randomization (figures 3 and ments for this outcome. The shorter duration of the
4, respectively). The differences between the two present study (6 months) compared with previous
budesonide/formoterol dosage strengths in their ef- studies (ranging from 12 months[17,18] to 3 years[13])
fects on pulmonary function suggest that the dose of may have contributed to the difference in statistical
ICS influences the efficacy of the combination treat- significance of the exacerbation results between the
ment in this population of patients with moderate to studies.
very severe COPD. Both budesonide/formoterol dosage strengths
Both budesonide/formoterol dosage strengths were well tolerated, with safety profiles consistent
demonstrated significantly greater improvements in with the known safety profiles of budesonide/for-
dyspnoea score compared with budesonide, formo- moterol in patients with COPD.[17,18] Notably, in this
terol and placebo in the present study. In addition, study, the incidence of pneumonia-related AEs,
both budesonide/formoterol dosage strengths dem- DAEs and SAEs did not differ across treatment
onstrated significantly greater improvements in al- groups. These results differ from previous studies in
most all other symptom variables compared with which an increased incidence of pneumonia was
budesonide and placebo. In contrast, the monocom- associated with fluticasone propionate/salmeterol
ponents did not show significant improvements in (500/50 μg twice daily) combination therapy[13,30,31]
most symptom variables compared with placebo. or fluticasone propionate (500 μg twice daily)
Previous studies have also demonstrated significant alone[13] in patients with COPD. Caution must be
symptom improvement in patients with COPD treat- used when interpreting the results of the pneumonia
ed with budesonide/formoterol DPI 320/9 μg ad- data in the present study and in the previous studies,
as the diagnosis of pneumonia was generally basedministered twice daily compared with those treated
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ions (Newtown, PA, USA) for writing assistance funded byon clinical judgment, without radiological confirma-
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